Tuesday, September 17

Healthcare

FDA approves Illumina's TruSight Oncology biomarker test

08/28/20241 Min Read

approves biomarker FDA Illumina039s Oncology test TruSight

Previous ArticleMedicare coverage of Novo Nordisk’s Wegovy could cost up to $145B annually

Next Article Eagle Pharmaceuticals receives delisting notification from Nasdaq